← Back to 1cP-LSD

1cP-LSD Stats & Data

Psychedelic Research-chemical

1cp Curie 1-cpa-lsd 1-cyclopropanoyl-lsd 1cplsd

NPS DataHub

MW539.59

FormulaC28H33N3O8

IUPAC4-(Cyclopropylcarbonyl)-N,N-diethyl-7-methyl-4,6,6a,7,8,9- hexahydroindolo[4,3-fg]quinoline-9-carboxamide

SMILESCCN(CC)C(=O)C1CN(C)C2Cc3cn(C(=O)C4CC4)c4cccc(C2=C1)c34.O=C([O-])C(O)C(O)C(=O)[O-]

InChIKeyZKEDTZOPMNCHFZ-UHFFFAOYSA-L

2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene

Chemical Class Lysergamide

Psychoactive Class Psychedelic

Half-Life Parent 1cP-LSD ≈ 2–4 h; primary active metabolite LSD ≈ 3–6 h. Subjective effects outlast plasma levels due to downstream signalling.

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

Other

prodrug of LSD

History & Culture

1cP-LSD was developed by Lizard Labs, a research chemical laboratory based in the Netherlands, as a legal alternative to LSD. The compound emerged on the grey market around 2019, reportedly created in anticipation of the impending prohibition of 1P-LSD in Germany. Like its predecessor, 1cP-LSD is widely regarded as a prodrug of LSD, converting to the parent compound following administration. The substance belongs to a broader wave of designer lysergamide analogs that have appeared on the research chemical market since the mid-2010s, including AL-LAD, ETH-LAD, and ALD-52. This pattern of novel analog development has been characteristic of the lysergamide research chemical scene, with each new prohibition prompting the emergence of structurally related alternatives. When Germany banned 1cP-LSD in July 2021, 1V-LSD promptly appeared on the market as its replacement, continuing this cycle of regulatory cat-and-mouse. Beyond its presence in the recreational research chemical market, 1cP-LSD has attracted some preliminary scientific attention. The compound has been investigated in veterinary contexts as a potential treatment for anxiety in dogs, representing an unusual application within psychedelic research.

Effect Profile

Curated + 11 Reports

Psychedelic 9.2

Strong visuals, headspace, and auditory effects with moderate body load

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

Effect Index A Fire Across the Nation — nervewing Effect Index Four Raccoons and a Squirrel — froggie Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 1cP-LSD The Drug Users Bible 1cP-LSD

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

19 minutes - 1.0 hours

45 minutes - 2.0 hours

3-5 hours

6-24 hours

Total: 8-10 hours

Sublingual

19 minutes - 1.0 hours

45 minutes - 2.0 hours

3-5 hours

6-24 hours

Total: 8-10 hours

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Parent 1cP-LSD ≈ 2–4 h; primary active metabolite LSD ≈ 3–6 h. Subjective effects outlast plasma levels due to downstream signalling.

Addiction Potential

Very low. Does not induce physical dependence and has little dopaminergic reinforcement. Compulsive redosing is uncommon but psychological habituation is possible.

Tolerance Decay

Full tolerance 1d Half tolerance 7d Baseline ~14d

Empirical user reports suggest marked tolerance next day with partial recovery over 7–14 days; values are indicative and individualized. Redosing same day extends duration more than intensity.

Cross-Tolerances

LSD

90% ●○○

1P-LSD

90% ●○○

AL-LAD

70% ●○○

Psilocybin and other 5‑HT2A psychedelics

60% ●○○

Experience Report Analysis

Erowid

11 Reports

2019–2025 Date Range

11 With Age Data

21 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 11 experience reports (11 Erowid)

11 Reports

21 Effects Detected

8 Positive

7 Adverse

6 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 8

Color Enhancement 72.7% 70%

Music Enhancement 72.7% 70%

Stimulation 63.6% 70%

Euphoria 54.5% 70%

Tactile Enhancement 45.5% 70%

Body High 45.5% 70%

Empathy 36.4% 70%

Introspection 27.3% 70%

Adverse Effects 7

Anxiety 63.6% 70%

Nausea 54.5% 70%

Muscle Tension 36.4% 70%

Jaw Clenching 27.3% 70%

Confusion 27.3% 70%

Pupil Dilation 27.3% 70%

Thought Loops 27.3% 70%

Real-World Dose Distribution

62K Doses

From 26 individual dose entries

Sublingual (n=17)

Median: 0.1mg 25th: 0.1mg 75th: 0.1mg 90th: 0.1mg

Oral (n=8)

Median: 0.12mg 25th: 0.09mg 75th: 0.2mg 90th: 0.27mg

mg/kg median: 0.002 mg/kg 75th: 0.004

Form / Preparation

Most common forms and preparations reported

Redose Patterns

Redosing behavior across 10 reports

20.0% Redosed

1.3 Avg Doses

20m Median Interval

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Canada	Unscheduled	Not listed as a controlled substance under Canadian drug control legislation. Remains legal to possess and purchase.
Czech Republic	Uncontrolled	Not designated as a controlled substance and does not appear on the national list of prohibited drugs.
Germany	Controlled (NpSG)	Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 2, 2021. Production and importation with intent to distribute, administration to others, and commercial trading are criminal offenses. Possession is prohibited but carries no penalty. Prior to this date, 1cP-LSD existed in a legal grey area as its cyclopropylcarbonyl group was not considered an alkyl radical under the original NpSG amendment regulation.
Japan	Controlled	Regulated under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.
Sweden	Dangerous substance	Sweden's public health agency proposed classification as a dangerous substance on December 18, 2019. Formally classified as such on April 22, 2021.
Turkey	Illegal	Classified as a controlled drug. Possession, production, supply, and importation are all criminal offenses.
United Kingdom	Controlled (PSA)	Covered by the Psychoactive Substances Act 2016, effective May 26, 2016. Production, supply, and importation are criminal offenses. Personal possession is not penalized under this legislation, though the substance cannot be legally sold for human consumption.

Harm Reduction

drugs.wiki

• 1cP-LSD (1-cyclopropionyl-lysergic acid diethylamide) is an N‑1 acylated lysergamide that functions as a prodrug to LSD; in vitro human-serum work and animal behavior show conversion to LSD and LSD‑like action. Expect essentially classic LSD pharmacology. [Brandt 2020; community corroboration]

• Relative potency per microgram is reported as similar to or modestly below LSD; do not assume equi-potency across batches—start low with new sources. [Erowid/Bluelight user reports]

• Reagent testing: use an indole test (Ehrlich) AND a lysergamide-specific test (Hofmann). Ehrlich can show false-positives on gel tabs or with other indoles (e.g., melatonin); Hofmann should develop blue/purplish for lysergamides over up to ~60 min. Use Marquis/Mecke to help rule out NBOMe/DOx. [Reddit ReagentTesting threads referencing Erowid guidance]

• Volumetric dosing is strongly recommended for accurate titration with microgram-active drugs. Prepare a measured solution (e.g., in ethanol/water), label clearly, and calculate dose with a volumetric converter. [TripSit]

• Storage stability: light, heat, oxygen, and moisture accelerate lysergamide degradation. For longer storage, keep blotters/pellets in airtight, lightproof containers with desiccant; refrigerate/freezer storage can extend shelf-life. Warm to room temp before opening to avoid condensation. [Bluelight HR FAQ]

• Mental health: avoid if history of psychosis, bipolar disorder, or uncontrolled severe anxiety. Use sitter, safe setting, and have a de-escalation plan. [General HR consensus]

• Rescue plan: a benzodiazepine (e.g., 1–2 mg lorazepam or 5–10 mg diazepam) can quell panic, but avoid preloading and mixing with alcohol/other depressants. Seek medical help for chest pain, seizures, or extreme agitation. [HR org guidance]

• HPPD/lingering visuals are uncommon but documented after LSD-like experiences; risk may rise with frequent/high-dose use and concurrent cannabis. Space sessions, especially after difficult trips. [HR summaries]

• Driving and tasks requiring full attention: impairment can persist beyond the subjective end of effects; wait at least 24 hours before driving. [Hi‑Ground]

• Cross-tolerance: strong with LSD and other 5‑HT2A psychedelics; spacing 7–14 days between sessions reduces tolerance and psychological wear. [Bluelight HR FAQ]

• Legal status varies and changes frequently; in some jurisdictions 1cP‑LSD is controlled or may be treated as an analogue of LSD. Verify locally before purchase/possession/use. [HR advisory]